NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CNTX

Context Therapeutics Inc

Apr 17 • 04:00PM ET

0.8431

Dollar change -0.0220
Percentage change -2.54	%

Healthcare • Biotechnology • USA • NASD

Peers: ONCT ZNTL KYMR CULP NBTX RNAZ BCYC XCUR TVRD CGTX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	41.67%	Shs Outstand	89.70M	Perf Week	24.11%
Market Cap	75.63M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	0.00%	Shs Float	52.33M	Perf Month	2.92%
Income	-26.73M	PEG	-	EPS next Q	-0.06	Inst Own	47.51%	Short Float	4.63%	Perf Quarter	-13.83%
Sales	0.00M	P/S	-	EPS this Y	41.74%	Inst Trans	169.58%	Short Ratio	14.91	Perf Half Y	-56.76%
Book/sh	1.06	P/B	0.79	EPS next Y	-28.36%	ROA	-46.81%	Short Interest	2.42M	Perf Year	-42.25%
Cash/sh	1.05	P/C	0.80	EPS next 5Y	-6.14%	ROE	-49.89%	52W Range	0.55 - 2.75	Perf YTD	-19.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.72%	ROI	-28.02%	52W High	-69.34%	Beta	1.81
Dividend TTM	-	Quick Ratio	35.55	Sales past 5Y	0.00%	Gross Margin	-	52W Low	53.29%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	35.55	EPS Y/Y TTM	65.02%	Oper. Margin	-	RSI (14)	57.00	Volatility	11.51% 16.27%
Employees	12	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	91.20%	Payout	-	Rel Volume	0.28	Prev Close	0.87
Sales Surprise	-	EPS Surprise	67.39%	Sales Q/Q	-	Earnings	Mar 20 AMC	Avg Volume	162.31K	Price	0.84
SMA20	15.85%	SMA50	8.85%	SMA200	-46.04%	Trades		Volume	45,589	Change	-2.54%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-25	Initiated	JMP Securities	Mkt Outperform	$4
Nov-25-24	Initiated	D. Boral Capital	Buy	$9
May-16-24	Initiated	Piper Sandler	Overweight	$4.50

Apr-09-25 07:30AM	Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 (GlobeNewswire)
Apr-04-25 08:51AM	Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos (Zacks) -16.68%
Apr-03-25 08:11AM	Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains (Zacks) +5.58%
Apr-01-25 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.95%
Mar-26-25 04:02PM	Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -8.57% -6.88%
04:22PM	Loading…
Mar-20-25 04:22PM	Context Therapeutics Reports Full Year 2024 Operating and Financial Results (GlobeNewswire) -5.98%
Feb-24-25 05:05PM	Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-15-25 11:29AM	Context doses first subject in Phase I cancer trial of CTIM-76 (Clinical Trials Arena)
Jan-14-25 04:58PM	Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 (GlobeNewswire)
Jan-13-25 07:30AM	Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors (GlobeNewswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
Nov-06-24 04:06PM	Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) -5.86%
Oct-23-24 07:30AM	Context Therapeutics to Participate in Upcoming Investor Conferences in November (GlobeNewswire) +11.50%
Oct-16-24 07:30AM	Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +5.13%
07:30AM	Loading…
Sep-23-24 07:30AM	BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody (GlobeNewswire) -7.96%
Sep-12-24 09:40AM	Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? (Zacks)
Sep-04-24 07:30AM	Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors (GlobeNewswire)
Aug-27-24 09:40AM	Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? (Zacks)
Aug-07-24 04:17PM	Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire)
Aug-01-24 07:30AM	Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations (GlobeNewswire)
Jul-10-24 07:30AM	Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 (GlobeNewswire)
May-30-24 06:11AM	Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight (InvestorPlace)
May-22-24 08:50PM	The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains (InvestorPlace)
May-20-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice (Zacks)
May-14-24 12:00PM	Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why (Zacks)
May-08-24 11:56PM	CNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +5.23%
04:06PM	Context Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
May-02-24 07:31AM	Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 (GlobeNewswire) +28.68%
07:30AM	Context Therapeutics Announces $100 Million Private Placement (GlobeNewswire)
07:30AM	Loading…
Apr-01-24 07:30AM	Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers (GlobeNewswire)
Mar-21-24 01:53PM	CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.96%
07:43AM	Context Therapeutics Reports Full Year 2023 Operating and Financial Results (GlobeNewswire)
Nov-09-23 04:15PM	Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire)
Oct-31-23 09:00AM	Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +13.64%
Sep-27-23 09:00AM	Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +16.22%
Aug-10-23 02:19PM	Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update (News Direct) +10.64%
Aug-09-23 04:10PM	Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire) -9.62%
Aug-01-23 07:30AM	Context Therapeutics to Participate in Two August 2023 Investor Conferences (GlobeNewswire) +7.27%
Jun-13-23 01:34PM	Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update (News Direct)
Jun-03-23 08:27AM	Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely? (Simply Wall St.)
May-10-23 04:39PM	Context Therapeutics Reports First Quarter 2023 Operating and Financial Results (GlobeNewswire) -6.37%
Apr-24-23 12:01PM	Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting (News Direct)
Apr-18-23 10:15AM	Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference (ACCESSWIRE)
Apr-04-23 12:00PM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023 (GlobeNewswire)
Apr-03-23 07:30AM	Context Therapeutics to Participate in Two April 2023 Investor Conferences (GlobeNewswire) +5.85%
Mar-22-23 05:08PM	Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates (GlobeNewswire) -7.59%
Mar-15-23 07:30AM	Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire)
Feb-13-23 08:52AM	UPDATE -- Diamond Equity Research Initiates Coverage on Context Therapeutics Inc. (NASDAQ: CNTX) (GlobeNewswire)
Feb-10-23 01:36PM	Lab Notes: Center for Breakthrough Medicines expands offerings; Researchers identify key 'gene signature' (American City Business Journals)
Feb-07-23 12:21PM	Context Therapeutics announces positive responses in Phase 2 OATH clinical trial (News Direct)
Feb-06-23 07:30AM	Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer (GlobeNewswire) +5.27%
Jan-31-23 07:30AM	Context Therapeutics Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer (GlobeNewswire) +55.20%
Jan-09-23 07:30AM	Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers (GlobeNewswire) +8.32%
Jan-04-23 07:30AM	Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones (GlobeNewswire) +9.79%
Dec-08-22 07:30AM	Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer (GlobeNewswire) -28.42%
Nov-29-22 07:30AM	Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors (GlobeNewswire)
Nov-27-22 07:36AM	Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-21-22 09:11AM	Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-22 04:14PM	Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Oct-20-22 07:30AM	Context Therapeutics to Participate in the ThinkEquity Conference (Newsfile)
Sep-27-22 11:41AM	Context Therapeutics halting 'noncritical R&D' spending to extend cash runway (American City Business Journals)
07:30AM	Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024 (GlobeNewswire)
Sep-06-22 12:50PM	A number of insiders bought Context Therapeutics Inc. (NASDAQ:CNTX) stock last year, which is great news for shareholders (Simply Wall St.)
07:30AM	Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 04:01PM	Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +9.73%
Aug-02-22 10:49AM	Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination (PR Newswire) +5.82%
Jul-05-22 09:22PM	'I wanted to build it here': Life sciences startup leaders talk about challenges of growing in Philadelphia (American City Business Journals)
May-15-22 10:12AM	Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-11-22 04:01PM	Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -5.15% +6.98%
May-05-22 07:30AM	Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting (GlobeNewswire)
Apr-11-22 07:30AM	Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) -22.24%
Apr-06-22 07:30AM	Context Therapeutics® to Participate in Two April 2022 Investor Conferences (GlobeNewswire)
Mar-30-22 04:33PM	A number of insiders bought Context Therapeutics Inc. (NASDAQ:CNTX) stock last year, which is great news for shareholders (Simply Wall St.)
Mar-23-22 04:01PM	Context Therapeutics® Reports Full Year 2021 Operating and Financial Results (GlobeNewswire)
Mar-08-22 06:12PM	Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) +9.62%
Feb-22-22 07:30AM	Context Therapeutics® to Participate in the Sachs 15th Annual European Life Sciences CEO Forum (GlobeNewswire)
Jan-05-22 04:01PM	Context Therapeutics® Strengthens Research & Development Team (GlobeNewswire) -9.12%
Jan-04-22 07:30AM	Context Therapeutics® to Participate in Two January 2022 Investor Conferences (GlobeNewswire)
Dec-10-21 11:11AM	ORCL Stock: 6 Reasons Why Oracle Investors Are Smiling Today (InvestorPlace) -14.06%
10:11AM	MITC Stock: The Lab-Grown Steak Breakthrough That Has MeaTech3D Looking Tasty Today (InvestorPlace)
09:54AM	CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today (InvestorPlace)
06:45AM	Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer (Benzinga)
Dec-09-21 06:00PM	Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium (GlobeNewswire) +24.21%
Dec-06-21 04:45PM	Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement (GlobeNewswire)
Dec-02-21 04:01PM	Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) -19.97% -7.50%
Dec-01-21 06:30PM	Context Therapeutics Inc. Announces $31.25 Million Private Placement (GlobeNewswire)
Nov-19-21 09:00AM	Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium (GlobeNewswire) +9.89%
Nov-01-21 04:02PM	Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer (GlobeNewswire) +6.98%
Oct-27-21 07:30AM	Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer (GlobeNewswire) -7.32%
Oct-22-21 04:05PM	Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters Over-allotment Option (GlobeNewswire) +13.29% +6.58%
Oct-20-21 04:57PM	Bitcoin Miner Stronghold Stock Pops 52% in First Day of Trading (Barrons.com)
Oct-19-21 07:14PM	Context Therapeutics® Announces Pricing of Initial Public Offering (GlobeNewswire)

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNTX

Context Therapeutics Inc

Upgrade your FINVIZ experience